Targeting hematological malignancies using fragment-based drug design
Structural Biology
Abstract
The project will be focused on the knowledge-based design of active compounds targeting several proteins or protein-protein interactions, which are implicated in the development of hematological malignancies (acute lymphoblastic leukemia and mixed-lineage leukemia). The compounds will be developed using the fragment-based approach. The work on this project provides the opportunity to acquire expertise in protein biochemistry, biophysics and structural biology (NMR spectroscopy and X-ray crystallography), as well as to get an insight into the rational drug design process through close collaboration with the medicinal and computational chemists.
Field of study: Physical Chemistry (Drug Discovery/Structural Biology)
References:
- Hnizda, A., et al.,Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. Leukemia 2018, 32 (6), 1393.
- Čermáková, K., et al., Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia. Cancer Research, 2014. 74 (18): 5139
Universities
PhD students must be enrolled in a partner university and will be employed by the IOCB Prague at the same time (part-time or full time), which results in a competitive salary (a scholarship from the university + a salary from the IOCB). Each university has its own process, terms, and deadlines for PhD applications, which is separate from the IOCB recruitment process. You may discuss the details with the respective PI.
University partners
How to apply
Please return to the PhD projects at IOCB Prague – Call for Applications 2020 page and follow the instructions.